

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天 辰 生 物

LongBio Pharma (Suzhou) Co., Ltd.

天辰生物醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1779)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by LongBio Pharma (Suzhou) Co., Ltd. (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

References are made to the prospectus of the Company dated May 28, 2026 (the “**Prospectus**”) and the announcement of the Company dated June 30, 2026 in relation to the full exercise of the over-allotment option. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Prospectus.

The Board proposed to amend the Articles of Association for the purposes of, among others, (i) reflecting the changes in the registered share capital and the structure of the share capital of the Company following the full exercise of the Over-allotment Option (articles 3, 6 and 20); and (ii) aligning the provisions of the Articles of Association more closely with the applicable domestic laws and regulations (article 69) (together, the “**Proposed Amendments**”).

Details of the Proposed Amendments are set out below:

Original Articles	Amended Articles
Article 3 Upon filing with the China Securities Regulatory Commission (the “CSRC”) on April 15, 2026 and obtaining the approval of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”), the Company conducted an initial public offering of 14,193,150 overseas listed foreign shares (with an over-allotment option to issue up to 2,128,950 H Shares), which were listed on the Main Board of the Hong Kong Stock Exchange on June 5, 2026.	Article 3 Upon filing with the China Securities Regulatory Commission (the “CSRC”) on April 15, 2026 and obtaining the approval of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”), the Company conducted an initial public offering of 14,193,150 overseas listed foreign shares (with an over-allotment option to issue up to 2,128,950 H Shares); <u>such over-allotment option was exercised in full, and a total of 2,128,950 H Shares were issued. The initially issued shares,</u> which were listed on the Main Board of the Hong Kong Stock Exchange on June 5, 2026, <u>and the over-allotment shares were listed on July 6, 2026.</u>
Article 6 The registered capital of the Company is RMB74,193,150.	Article 6 The registered capital of the Company is RMB74,193,150<u>76,322,100.</u>
Article 20 The total number of shares of the Company is 74,193,150, all of which are ordinary shares. Upon completion of the initial public offering of H Shares, the share capital structure of the Company as at the listing date shall be: 74,193,150 ordinary shares, including 1,262,882 domestic unlisted shares and 72,930,268 H Shares. If at any time the shares of the Company are divided into different classes, any variation of the rights attached to any class of shares shall be subject to approval by a special resolution passed by the Shareholders of that affected class.	Article 20 The total number of shares of the Company is ~~74,193,150~~<u>76,322,100</u>, all of which are ordinary shares. Upon completion of the initial public offering of H Shares <u>and the full exercise of the over-allotment option,</u> the share capital structure ~~of the Company as at the listing date shall be:~~ ~~74,193,150~~<u>76,322,100</u> ordinary shares, including 1,262,882 domestic unlisted shares and ~~72,930,268~~<u>75,059,218</u> H Shares. If at any time the shares of the Company are divided into different classes, any variation of the rights attached to any class of shares shall be subject to approval by a special resolution passed by the Shareholders of that affected class.

Original Articles	Amended Articles
Article 69 When the Company convenes a general meeting, all Directors shall attend the meeting, and the general manager and other senior management shall attend the meeting as non-voting participants.	Article 69 When the Company convenes a general meeting, ~~all Directors shall attend the meeting,~~ <u>if any Directors and senior management are required to attend the meeting, such Directors</u> and the ~~general manager and other senior management~~ shall attend the meeting as non-voting participants <u>and respond to the enquiries from the Shareholders.</u>

Save as the aforesaid Proposed Amendments, the other provisions of the existing Articles of Association shall remain unchanged. The Proposed Amendments are prepared in Chinese, and the English translation is for reference only. In the event of any discrepancy between the Chinese and the English versions of the Proposed Amendments and/or the Articles of Association, the Chinese version shall prevail.

The Proposed Amendments are subject to the approval of the shareholders of the Company by way of special resolution at the forthcoming extraordinary general meeting (the “EGM”) and, if approved, will become effective upon such approval. Prior to the passing of the relevant special resolution at the EGM, the existing Articles of Association shall remain valid. A circular containing, among other matters, details of the Proposed Amendments, together with a notice convening the EGM will be published on the websites of the Stock Exchange and the Company, and despatched to the Shareholders (if requested), in due course.

By order of the Board
LongBio Pharma (Suzhou) Co., Ltd.
Dr. Liu Heng
Chairman of the Board and Executive Director

Hong Kong, October 9, 2026

As at the date of this announcement, the Board comprises (i) Dr. LIU Heng, Dr. SUN Bill Nai-chau and Mr. XIE Ming as executive Directors; (ii) Mr. LIN Jian, Ms. GU Qin, Dr. XUE Di and Mr. XUE Kailu as non-executive Directors; and (iii) Mr. SIU Paul Yu Hay, Mr. RUAN Tim, Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.